A plethora of scientific evidence demonstrates a growth-promoting, anti-apoptotic action of EPO and other ESAs on non-hematopoietic cells, both normal and malignant, and this is supported by numerous clinical observations showing adverse effects of EPO administration on the clinical management of tumor growth and progression. This evidence concerns the gene EPO and neoplasm.